These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 18997093

  • 1. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
    Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, Liu KR, Hu FR.
    Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
    Kim TI, Kim SW, Kim S, Kim T, Kim EK.
    Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
    [Abstract] [Full Text] [Related]

  • 3. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.
    Lin CT, Hu FR, Kuo KT, Chen YM, Chu HS, Lin YH, Chen WL.
    Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6277-85. PubMed ID: 20435600
    [Abstract] [Full Text] [Related]

  • 4. The effect of subconjunctival suramin on corneal neovascularization in rabbits.
    Lee HS, Chung SK.
    Cornea; 2010 Jan; 29(1):86-92. PubMed ID: 19907290
    [Abstract] [Full Text] [Related]

  • 5. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
    Avisar I, Weinberger D, Kremer I.
    Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
    Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA.
    Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
    [Abstract] [Full Text] [Related]

  • 7. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.
    Qian CX, Bahar I, Levinger E, Rootman D.
    Cornea; 2008 Oct; 27(9):1090-2. PubMed ID: 18812781
    [Abstract] [Full Text] [Related]

  • 8. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
    Hurmeric V, Mumcuoglu T, Erdurman C, Kurt B, Dagli O, Durukan AH.
    Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
    [Abstract] [Full Text] [Related]

  • 9. Subconjunctival bevacizumab injection for corneal neovascularization.
    Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A.
    Cornea; 2008 Feb; 27(2):142-7. PubMed ID: 18216566
    [Abstract] [Full Text] [Related]

  • 10. The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.
    Kang S, Chung SK.
    Cornea; 2010 Feb; 29(2):192-6. PubMed ID: 20098156
    [Abstract] [Full Text] [Related]

  • 11. Comparative study of ranibizumab and bevacizumab on corneal neovascularization in rabbits.
    Kim EK, Kong SJ, Chung SK.
    Cornea; 2014 Jan; 33(1):60-4. PubMed ID: 24240485
    [Abstract] [Full Text] [Related]

  • 12. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
    Hashemian MN, Moghimi S, Kiumehr S, Riazi M, Amoli FA.
    Ophthalmic Res; 2009 Jan; 42(2):90-5. PubMed ID: 19546599
    [Abstract] [Full Text] [Related]

  • 13. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits.
    Kadar T, Amir A, Cohen L, Cohen M, Sahar R, Gutman H, Horwitz V, Dachir S.
    Curr Eye Res; 2014 May; 39(5):439-50. PubMed ID: 24215293
    [Abstract] [Full Text] [Related]

  • 14. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.
    Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C.
    Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2545-52. PubMed ID: 17525183
    [Abstract] [Full Text] [Related]

  • 15. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.
    Yoo AR, Chung SK.
    Cornea; 2014 Oct; 33(10):1088-94. PubMed ID: 25119962
    [Abstract] [Full Text] [Related]

  • 16. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
    Hashemian MN, Z-Mehrjardi H, Moghimi S, Tahvildari M, Mojazi-Amiri H.
    Ophthalmic Res; 2011 Oct; 46(1):50-4. PubMed ID: 21212709
    [Abstract] [Full Text] [Related]

  • 17. Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization.
    Zhang Z, Ma JX, Gao G, Li C, Luo L, Zhang M, Yang W, Jiang A, Kuang W, Xu L, Chen J, Liu Z.
    Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4062-71. PubMed ID: 16249481
    [Abstract] [Full Text] [Related]

  • 18. Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition.
    Chu HS, Hu FR, Yang CM, Yeh PT, Chen YM, Hou YC, Chen WL.
    Cornea; 2011 Jan; 30(1):60-6. PubMed ID: 20847676
    [Abstract] [Full Text] [Related]

  • 19. Subconjunctival bevacizumab for corneal neovascularization.
    Zaki AA, Farid SF.
    Acta Ophthalmol; 2010 Dec; 88(8):868-71. PubMed ID: 19519730
    [Abstract] [Full Text] [Related]

  • 20. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.
    Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A.
    Curr Eye Res; 2008 Jan; 33(1):23-8. PubMed ID: 18214740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.